SARS-CoV-2 host-viral interaction targets (SARS-CoV-2 HVI)

SARS-CoV-2 host-viral interaction targets represent a broad category of proteins and molecular pathways essential for the life cycle of the SARS-CoV-2 virus within a human host. This group includes viral proteins such as the Spike (S) protein, Main Protease (Mpro), and RNA-dependent RNA polymerase (RdRp), as well as host factors like Angiotensin-converting enzyme 2 (ACE2) and Transmembrane protease serine 2 (TMPRSS2). The primary biological function of these interactions is to facilitate viral attachment, membrane fusion, genomic replication, and assembly. In the context of COVID-19, these interactions drive the pathogenesis of the disease, leading to respiratory failure and systemic inflammation. Therapeutic strategies targeting these interactions include monoclonal antibodies that block viral entry, small-molecule antivirals that inhibit replication enzymes, and host-directed therapies to mitigate the hyperinflammatory response. Because this term encompasses multiple distinct proteins rather than a single molecular entity, it is classified as a collective target category.

Other names

SARS-CoV-2 interactomeCOVID-19 host-pathogen interactionsSARS-CoV-2 host cell entry factorsSARS-CoV-2 viral-host protein-protein interactions

Inhibition of viral entry (blocking Spike-ACE2 interaction), inhibition of viral proteolysis (Mpro inhibitors), inhibition of viral RNA synthesis (RdRp inhibitors), and modulation of host inflammatory response.